Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs

[1]  Shile Huang,et al.  Targeting mTOR signaling for cancer therapy. , 2003, Current opinion in pharmacology.

[2]  W. Friedrichs,et al.  Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  Brett L Carlson,et al.  Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy. , 2002, Cancer research.

[4]  Jie Chen,et al.  A novel pathway regulating the mammalian target of rapamycin (mTOR) signaling. , 2002, Biochemical pharmacology.

[5]  Guido Reifenberger,et al.  Pten signaling in gliomas. , 2002, Neuro-oncology.

[6]  C. James,et al.  PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. , 2001, Journal of the National Cancer Institute.

[7]  Hong Wu,et al.  Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[8]  D. Louis,et al.  PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis. , 2001, The American journal of pathology.

[9]  B. Geoerger,et al.  Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. , 2001, Cancer research.

[10]  M. Hidalgo,et al.  The rapamycin-sensitive signal transduction pathway as a target for cancer therapy , 2000, Oncogene.

[11]  Tobias Schmelzle,et al.  TOR, a Central Controller of Cell Growth , 2000, Cell.

[12]  C. Groth,et al.  Pharmacokinetics and Safety of Single Oral Doses of Sirolimus (Rapamycin) in Healthy Male Volunteers , 2000, Therapeutic drug monitoring.

[13]  M J Gleason,et al.  Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  W. Yung,et al.  Advances in Brief Differential Expression of MMAC / PTEN in Glioblastoma Multiforme : Relationship to Localization and Prognosis 1 , 1999 .

[15]  M. Berger,et al.  Phase I study of paclitaxel in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Dodge,et al.  Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase. , 1994, Cancer research.

[17]  K Y Hui,et al.  A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). , 1994, The Journal of biological chemistry.

[18]  T. Cascino,et al.  Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.